1073723-10-0

Basic information

• Product Name: ethyl 1-benzyl-5,5-dimethyl-4-oxopiperidine-3-carboxylate
• Synonyms: ethyl 1-benzyl-5,5-dimethyl-4-oxopiperidine-3-carboxylate
• CAS NO: 1073723-10-0
• Molecular Weight: 289.375
• Mol File: 1073723-10-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: ethyl 1-benzyl-5,5-dimethyl-4-oxopiperidine-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 1-benzyl-5,5-dimethyl-4-oxopiperidine-3-carboxylate(1073723-10-0)
• EPA Substance Registry System: ethyl 1-benzyl-5,5-dimethyl-4-oxopiperidine-3-carboxylate(1073723-10-0)

Safety Data

• Hazardous Substances Data: 1073723-10-0(Hazardous Substances Data)

Upstream product

• 173186-91-9 N-benzyl-3,3-dimethylpiperidine-4-one 
• 105-58-8 Diethyl carbonate 
• 1332455-38-5 C₁₉H₂₉NO₄ 
• 1195298-57-7 C₁₂H₂₃NO₄ 
• 59193-77-0 3-amino-2,2-dimethylpropionic acid ethyl ester 
• 1572-98-1 2-cyano-2-methyl-propionic acid ethyl ester 
• 623-49-4 ethyl cyanoformate 

Downstream Products

• 1332455-39-6 C₁₆H₁₉N₃O 
• 1332455-40-9 C₁₆H₁₈ClN₃ 
• 1332455-41-0 C₂₄H₃₂N₄O₂ 

Relevant articles and documents

TASK CHANNEL ANTAGONISTS

This invention relates to TASK-1 and/or TASK-3 antagonists and/or their pharmaceutically acceptable salts, compositions and methods for treating and preventing disorders which are caused by activation or by an activated TASK-1 and/or TASK-3, and disorders

CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF

Provided are a condensed pyridine derivative having a serotonin 5-HT2C receptor activation action, a prophylactic or therapeutic agent for a lower urinary tract symptom, obesity and/or organ prolapse and the like containing the condensed pyridine derivative, a screening method for a substance that increases leak point pressure upon a rise in the intravesical pressure or a prophylactic or therapeutic drug for stress urinary incontinence, a prophylactic or therapeutic drug for cystoceles or enteroceles, containing a substance that activates serotonin 5-HT2C receptor, and a method of screening for a therapeutic drug for cystoceles or enteroceles, including increasing an intravesical pressure after bilateral transection of the hypogastric nerve and pudendal nerve of an animal, and measuring a closure response in the urethra, the rectum or the vagina observed at that time. A serotonin 5-HT2C receptor activator containing a compound represented by the formula: wherein each symbol is as defined in the specification, or a salt thereof.